4.5 Review

From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein

Journal

JOURNAL OF NEUROCHEMISTRY
Volume 126, Issue 2, Pages 183-190

Publisher

WILEY
DOI: 10.1111/jnc.12239

Keywords

A peptide; AICD; Alzheimer's disease; APP; epigenetics; synaptic spines

Funding

  1. UK Medical Research Council
  2. Alzheimer's Research UK
  3. Programme RAS Fundamental Sciences for Medicine
  4. Belgian Fonds pour la Recherche Scientifique (FNRS-FRS)
  5. Interuniversity Attraction Poles Programme-Belgian State-Belgian Science Policy
  6. Programme d'excellence Marshall Diane convention
  7. Alzheimers Research UK [ARUK-ESG2013-1] Funding Source: researchfish

Ask authors/readers for more resources

Despite intensive studies of the secretase-mediated processing of the amyloid precursor protein (APP) to form the amyloid -peptide (A), in relation to Alzheimer's disease (AD), no new therapeutic agents have reached the clinics based on reducing A levels through the use of secretase inhibitors or immunotherapy. Furthermore, the normal neuronal functions of APP and its various metabolites still remain under-investigated and unclear. Here, we highlight emerging areas of APP function that may provide new insights into synaptic development, cognition, and gene regulation. By modulating expression levels of endogenous APP in primary cortical neurons, the frequency and amplitude of calcium oscillations is modified, implying a key role for APP in maintaining neuronal calcium homeostasis essential for synaptic transmission. Disruption of this homeostatic mechanism predisposes to aging and AD. Synaptic spine loss is a feature of neurogeneration resulting in learning and memory deficits, and emerging evidence indicates a role for APP, probably mediated via one or more of its metabolites, in spine structure and functions. The intracellular domain of APP (AICD) has also emerged as a key epigenetic regulator of gene expression controlling a diverse range of genes, including APP itself, the amyloid-degrading enzyme neprilysin, and aquaporin-1. A fuller understanding of the physiological and pathological actions of APP and its metabolic network could provide new opportunities for therapeutic intervention in AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available